IXI vs. HEMO, NSCI, RLM, ONC, SNG, GENF, BVX, CIZ, IMM, and ROQ
Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include Hemogenyx Pharmaceuticals (HEMO), NetScientific (NSCI), Realm Therapeutics (RLM), Oncimmune (ONC), Synairgen (SNG), Genflow Biosciences (GENF), BiVictriX Therapeutics (BVX), Cizzle Biotechnology (CIZ), ImmuPharma (IMM), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.
IXICO (LON:IXI) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
In the previous week, Hemogenyx Pharmaceuticals had 1 more articles in the media than IXICO. MarketBeat recorded 1 mentions for Hemogenyx Pharmaceuticals and 0 mentions for IXICO. Hemogenyx Pharmaceuticals' average media sentiment score of 0.76 beat IXICO's score of 0.00 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.
IXICO has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.21, indicating that its stock price is 221% more volatile than the S&P 500.
IXICO has higher revenue and earnings than Hemogenyx Pharmaceuticals. IXICO is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
56.3% of IXICO shares are held by institutional investors. Comparatively, 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 30.4% of IXICO shares are held by company insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
IXICO received 89 more outperform votes than Hemogenyx Pharmaceuticals when rated by MarketBeat users. Likewise, 71.64% of users gave IXICO an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.
Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -31.10%. IXICO's return on equity of -16.99% beat Hemogenyx Pharmaceuticals' return on equity.
Summary
IXICO beats Hemogenyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get IXICO News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free IXI Stock Alerts